Access Financial Services Inc. acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,447 shares of the medical research company’s stock, valued at approximately $249,000.
Several other hedge funds and other institutional investors have also bought and sold shares of AMGN. First Republic Investment Management Inc. raised its position in Amgen by 3.0% in the fourth quarter. First Republic Investment Management Inc. now owns 558,210 shares of the medical research company’s stock valued at $81,616,000 after buying an additional 16,521 shares during the last quarter. Camelot Portfolios LLC purchased a new position in shares of Amgen during the first quarter worth about $1,429,000. Private Asset Management Inc. increased its position in shares of Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares in the last quarter. Cadence Bank NA increased its position in shares of Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares in the last quarter. Finally, Quest Investment Management Inc. OR increased its position in shares of Amgen by 2,608.6% in the fourth quarter. Quest Investment Management Inc. OR now owns 59,372 shares of the medical research company’s stock worth $8,681,000 after buying an additional 57,180 shares in the last quarter. 79.53% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (AMGN) traded up 0.19% during trading on Friday, reaching $169.43. 1,571,584 shares of the company’s stock traded hands. The company has a market capitalization of $123.63 billion, a price-to-earnings ratio of 15.43 and a beta of 1.35. The company has a 50 day moving average of $174.60 and a 200-day moving average of $167.37. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company earned $2.84 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.
A number of research analysts recently issued reports on the stock. BidaskClub downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Argus lifted their price target on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. UBS AG set a $180.00 price target on shares of Amgen and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Deutsche Bank AG reiterated a “hold” rating and issued a $174.00 price target (up previously from $172.00) on shares of Amgen in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and an average target price of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.